Protocol Ledger

NCT04203316 · Phase II · ACTIVE NOT RECRUITING

Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation

Interventional Phase II clinical trial protocol NCT04203316 sponsored by Children's Oncology Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-08-14 Enrollment: 1 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04203316
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04203316
Protocol FieldVerified Registry Value
NCT IdentifierNCT04203316
Consolidated Lead SponsorChildren's Oncology Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment1 participants (ACTUAL)
Registered Start Date2023-08-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04203316
Hospital Research SiteLocationSite Profile
Children's Hospital of AlabamaBirmingham, ALOpen Hospital Dossier ->
Arkansas Children's HospitalLittle Rock, AROpen Hospital Dossier ->
Children's Hospital ColoradoAurora, COOpen Hospital Dossier ->
MedStar Georgetown University HospitalWashington D.C, DCOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI